Company Analysis

Lineage Cell Therapeutics, Inc. (LCTX)

NYSE: LCTX · Biological Products, (No Diagnostic Substances) · Carlsbad, CA · filing with the SEC since 1996
Grade5.6
◀ Past 6.1● Present 5.5▶ Future 5.3
1 est.

Who runs Lineage Cell Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Culley Brian M
President and CEO. First filing Sep 2018, latest Mar 12, 2026, 7 filings in all.
Officers reporting now
3
of 9 people with a filing in the last fifteen months
Directors reporting now
6
27 people on the record since 2006
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Culley Brian MPresident and CEOSep 2018Mar 12, 2026none
Howe Jill AnnChief Financial OfficerNov 2022Mar 6, 2026none
Samuel George A. IIIGeneral Counsel and SecretarySep 2021Mar 6, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Amin DiptidirectorApr 2021Jul 2, 2026none
Andrews Deborah JdirectorApr 2014Jul 2, 2026none
Bradsher Neal CdirectorJan 2006Jul 2, 2026none
Jayasuriya AnuladirectorMay 2021Jul 2, 2026none
Mulroy Michael H.directorOct 2014Jul 2, 2026none
Russell Angus C.directorDec 2014Jul 2, 2026none
Earlier names on the record20, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton LCTX · research, not advice